Ascendis Pharma
Aug 16, 2024
YORVIPATH for Hypoparathyroidism Treatment – The First and Only Therapy for Therapy for Adults
A year after rejecting it, the FDA has now approved Ascendis Pharma’s once-daily injectable YORVIPATH for hypoparathyroidism treatment. Ascendis Pharma’s YORVIPATH (palopegteriparatide), formerly called TransCon PTH, has been approved for the treatment of adults with hypoparathyroidism. This rare condition, charact...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
